1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Cytokinetics Sees Enough Evidence To Move Reldesemtiv Into Phase III For ALS

 
• By Mandy Jackson

The Astellas-partnered drug did not reach statistical significance on any FORTITUDE-ALS endpoints, but clinically significant results over time justify a longer Phase III study that's likely to enroll ALS patients with a faster rate of disease progression.

Titled book Amyotrophic Lateral Sclerosis along with medical equipment, conceptual image - Image
Cytokinetics may move reldesemtiv into Phase III in ALS in 2020. • Source: Shutterstock

Cytokinetics Inc. saw no statistically significant results on the major primary and secondary endpoints in its Phase II clinical trial of reldesemtiv in amyotrophic lateral sclerosis (ALS), but the company and partner Astellas Pharma Inc. still plan to start a Phase III trial, possibly in 2020, based on clinically meaningful data points in the mid-stage FORTITUDE-ALS study.

Reldesemtiv is the second ALS candidate from Cytokinetics' pipeline of muscle activators that has looked promising enough to the company...

More from Clinical Trials

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.